Shopping Cart
Remove All
Your shopping cart is currently empty
Brazikumab
😃Good
Catalog No. T76934Cas No. 1610353-18-8
Alias MEDI2070, MEDI 2070, AMG139, AMG 139
Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.
Brazikumab
Brazikumab
😃Good
Catalog No. T76934Alias MEDI2070, MEDI 2070, AMG139, AMG 139Cas No. 1610353-18-8
Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $516 | In Stock | In Stock | |
| 10 mg | $828 | - | In Stock | |
| 25 mg | $1,230 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98% (SDS-PAGE); 97.7% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research. |
| Targets&IC50 | IL-23:0.138 nM (Kd) |
| In vitro | Brazikumab is a human IgG2 monoclonal antibody that binds to the p19 subunit with high affinity and has a KD of 0.138 nM against human IL-23. Brazikumab inhibits the binding of recombinant and natural IL-23 to receptors that are stably expressed in COS cells with IC50 of 188 and 284 pM, respectively. Brazikumab inhibits in vitro production of IFN-γ in NK cells stimulated by human natural or recombinant IL-23 (bound to IL-18) with IC50 of 238 and 93 pM, respectively. [1] |
| Synonyms | MEDI2070, MEDI 2070, AMG139, AMG 139 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-23 |
| Molecular Weight | 145.78 kDa |
| Cas No. | 1610353-18-8 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | IgG2SA |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Brazikumab | purchase Brazikumab | Brazikumab cost | order Brazikumab | Brazikumab in vitro | Brazikumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.